证券代码：300138 证券简称：晨光生物 公告编号：2025—067 晨光生物科技集团股份有限公司 2025 年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年6月30日。 2、预计的业绩：同向上升。 | 项 目 | 本报告期 | | | 上年同期 | | | | --- | --- | --- | --- | --- | --- | --- | | | （2025 月） | 年 1—6 | | （2024 1—6 | 年 | 月） | | 营业收入 | 346,000 万元—376,000 万元 | | | 349,092.99 万元 | | | | | 比上年同期增长：-0.89%至 | | 7.71% | | | | | 归属于上市公司股东 的净利润 | 盈利：20,200 万元—23,200 | | 万元 | 盈利：9,983.46 | | 万元 | | | 比上年同期增长：102.33%至 132.38% | | | | | | | 归属于上市公司股东 扣除非经常 ...

晨光生物（300138）公告，预计2025年1月1日至2025年6月30日，营业收入34.6亿元—37.6亿元，同比增 长-0.89%至7.71%。归属于上市公司股东的净利润预计为2.02亿元—2.32亿元，同比增长102.33%至 132.38%。归属于上市公司股东扣除非经常性损益后的净利润预计为1.74亿元—2.04亿元，同比增长 117.40%至154.88%。 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—066 晨光生物科技集团股份有限公司 一、担保情况概述 晨光生物科技集团股份有限公司（简称"公司"）于 2025 年 4 月 3 日召开 第五届董事会第十五次会议、2025 年 5 月 6 日召开 2024 年年度股东大会，审议 通过了《关于公司与子公司或子公司之间融资担保的议案》，同意公司及合并报 表范围内各级子公司在2024年年度股东大会审议通过之日起至2025年年度股东 大会召开日，向融资机构申请办理各类融资业务余额不超 70 亿元；融资担保方 式涉及公司合并报表范围内各主体之间担保：公司向合并报表范围内各级子公司 或各级子公司之间融资担保余额不超过 25 亿元，其中：向子公司新疆晨光生物 科技股份有限公司（简称"新疆晨光"）及其合并报表范围内子公司提供担保的 余额不超过 20.5 亿元（含新疆晨光合并报表范围内各主体互相担保），向其他 子公司提供担保或其他子公司之间互相担保的余额不超过 4.5 亿元。公司股东大 会授权管理层在融资担保余额不超过 25 亿元的前提下，结合合并报表范围内各 子公司资产负债率、融资授信及放款等情况，具体调整被担 ...

Core Viewpoint - The natural pigment safflower yellow has significant applications in food, cosmetics, and pharmaceuticals, with a growing market size in China expected to reach 830 million yuan in 2024, reflecting a year-on-year increase of 23.88% [1][11]. Group 1: Industry Overview - Safflower yellow is a natural yellow pigment extracted from safflower petals, recognized for its safety and stability compared to synthetic dyes, aligning with modern consumer preferences for health and environmental sustainability [1][11]. - The pigment exhibits various pharmacological functions, including antioxidant and anti-inflammatory properties, which may aid in treating cardiovascular and inflammatory diseases [1][3]. - The extraction methods for safflower yellow include water extraction, organic solvent precipitation, and enzyme extraction, with the latter two methods yielding higher purity products [3][5]. Group 2: Industry Chain - The safflower yellow industry chain consists of three segments: upstream (safflower cultivation and supply of auxiliary materials), midstream (production and manufacturing of safflower yellow), and downstream (applications in pharmaceuticals, food, textiles, and cosmetics) [5]. Group 3: Market Demand and Trends - The demand for safflower yellow is expected to grow due to increasing consumer awareness of food safety and health, with applications expanding in food, pharmaceuticals, and cosmetics [18]. - Technological innovations in extraction methods and production processes are enhancing efficiency and reducing costs, contributing to the industry's growth [19][20]. - The competitive landscape is diversifying, with both domestic and international players vying for market share, necessitating continuous investment in research and development [21]. Group 4: Key Companies - Notable companies in the safflower yellow industry include Morning Light Bio-Technology Group, Yunnan Tonghai Yang's Natural Products Co., and Henan Zhongda Hengyuan Biotechnology Co., among others, which are primarily located in Hebei, Henan, Yunnan, and Hubei [2][13][14].

证券代码：300138 证券简称：晨光生物 公告编号：2025—064 晨光生物科技集团股份有限公司 结合自身资金情况，近日喀什蛋白归还了乌鲁木齐招行上述借款，《最高额 不可撤销担保书》项下担保的借款全部还款完毕，公司减少了对应的 3,000 万担 保义务。 关于子公司归还银行借款暨为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）对合并报表范围内子 公司银行借款担保情况因业务进展发生了变动，现公告如下： 一、对外担保基本情况及进展 1、结合自身经营流动资金需求，经公司 2023 年年度股东大会决议，晨光生 物科技集团图木舒克有限公司（以下简称"图木舒克晨光"，系子公司新疆晨光 生物科技股份有限公司全资子公司，穿透后为公司控股子公司）前期向中国银行 股份有限公司喀什地区分行（以下简称"中国银行"）申请办理了 10,000 万元 流动资金借款，担保方式：公司保证担保。 公司与中国银行就上述借款事宜签署了《最高额保证合同》，被担保的最高 债权额为：所担保债权之最高本金余额 10,000 万元 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"或"晨光生物"）于近 日正式取得了国家知识产权局颁发的四项商标注册证，子公司——晨光生物科技 集团邯郸有限公司（以下简称"邯郸晨光"）正式取得了国家版权局颁发的一项 作品登记证书，具体情况如下： 证券代码：300138 证券简称：晨光生物 公告编号：2025—065 晨光生物科技集团股份有限公司 关于取得商标注册证和作品登记证书的公告 | 商标图形或字样 | 商标编号 | 注册 | 核定使用商品/服务项目 | 有效期限 | 注册 | | --- | --- | --- | --- | --- | --- | | | | 类别 | | | 人 | | | 80511763 80511758 | 29 类 | 食用油脂；食用油；食用玉米 油；食用芝麻油；食用棕榈油； 食用橄榄油；食用葵花籽油； 食用亚麻籽油；食用豆油 | 2025.05.14 至 | 晨光 生物 | | | | | 清洁用油；香精油；蛋糕用调 味香精油；香料；食物用调味 | 2035.05.13 | | ...

Core Viewpoint - Chenguang Biotech has achieved a significant innovation by obtaining approval for sodium chlorogenic acid as a new feed additive, marking a pioneering breakthrough in China's feed industry [1] Group 1: Product Innovation - Sodium chlorogenic acid is extracted from stevia leaves and has been developed using a proprietary short-chain alcohol mixed solution extraction technology, enhancing the yield of the main product, steviol glycosides, while also creating a new product with antioxidant, anti-inflammatory, and antiviral properties [1] - This innovation fills a gap in the global market and improves resource utilization, opening new avenues for the comprehensive use of stevia [1] Group 2: Application in Livestock - In the livestock sector, sodium chlorogenic acid has demonstrated significant functional value, effectively enhancing the immune and antioxidant capabilities of weaned piglets and late-stage laying hens, optimizing gut microbiota, and improving nutrient absorption efficiency [1] - Experimental data indicates that its safety and efficacy meet industry-leading standards [1] Group 3: Market Position and Future Prospects - Chenguang Biotech specializes in the extraction, separation, purification, and application of plant active ingredients, with a diverse product range that includes natural pigments, spices, sweeteners, and health products, positioning it as a leader in the industry [2] - The successful development and application of sodium chlorogenic acid will further solidify Chenguang Biotech's leading position, enhance its brand influence, and increase market competitiveness [2] - The R&D team is accelerating the exploration of sodium chlorogenic acid's applications in food, health products, and pharmaceuticals, with potential in functional food development and chronic disease prevention [2]

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

晨光生物（300138）公告，公司第五届董事会第十七次会议、第五届监事会第十六次会议审议通过了 《关于部分募集资金投资项目延期的议案》，同意对"天然植物综合提取一体化项目(一期)"、"营养药用 综合提取项目(一期)"及"赞比亚土地开发及配套设施建设项目"达到预定可使用状态的时间进行延期。延 期后的预计完成时间分别为2027年6月30日、2027年4月30日、2026年12月31日。延期原因为全球经济环 境变化、市场开拓缓慢、生产工艺持续优化等因素影响。公司将严格遵守相关规定，科学决策，加强监 督，确保募集资金使用的合法有效。本次延期不会对公司正常经营产生重大不利影响。 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—061 表决结果：同意六票；反对零票；弃权零票。 议案具体内容、监事会、保荐机构发表的意见，详见巨潮资讯网同期披露的 相关公告文件。 特此公告 晨光生物科技集团股份有限公司董事会 2025 年 6 月 19 日 第五届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）董事会于 2025 年 6 月 13 日以专人送达、邮件方式向全体董事发出第五届董事会第十七次会议通知， 会议于 2025 年 6 月 19 日在公司会议室以现场与通讯相结合的方式召开。本次会 议由董事长卢庆国先生主持，应出席会议董事六人，实际出席会议董事六人（董 事卢颖，独立董事牛翃、戴小枫、厉梁秋以通讯表决方式参加），公司监事、高 级管理人员列席了本次会议，本次会议召开符合《公司法》《公司章程》等有关 规定。经与会董事研究、讨论，审议通过以下议案： 一、 审议通过了《关于部分募集资金投资项目延期的议案》 根据部分募集资金投资项目的实际建设情况和投资进度，为保 ...